Almost 600,000 Inhalers Recalled by GlaxoSmithKline
Inhaler Recalled for Improper Dosing
GlaxoSmithKLine (GSK) is recalling roughly 593,000 “Ventolin HFA 200D” inhalers from the United States. The defective inhalers at issue were manufactured at GSK’s factory in Zebulon, North Carolina.
GSK initiated this recall – which the FDA approved – after receiving multiple complaints that the inhalers were leaking. As a result GSK is concerned that the Ventolin HFA 200D inhalers contain less medicine than they are supposed to. GSK claims that the defects in these inhalers don’t pose an immediate threat to patient safety, so individual consumers have not been instructed to return the defective devices. Hospitals, pharmacies, retailers, and wholesalers, however, have been instructed to return their stock of Ventolin HFA 200D inhalers.
Most American consumers use pharmaceuticals and/or medical devices on a daily basis, but many are unaware when the drug they take or device they use is recalled. At GoldenbergLaw we believe that when a company realizes their drug or device isn’t working as intended, it should immediately be brought to the attention of its customers. Unfortunately, too many corporations decide to hide or understate the truth about defects in their products that could seriously injure, or even kill, their consumers. To GSK, improper dosage doesn’t pose an immediate threat to consumer safety. But to the person suffering from severe asthma, improper dosage could cause a very scary and potentially harmful situation.
We have helped thousands of clients recover emotionally and financially from injuries caused by no fault of their own. If you have a potential client that has been seriously injured after using a defective drug, product, or device that they believed to be safe, give us a call at 612-333-4662.